We want to transform the landscape of cancer treatment and significantly improve the lives of cancer patients worldwide. 

At Pfizer, we strive to bring innovative treatments to the forefront by developing therapies that provide maximum efficacy while minimizing adverse effects for the patient.

Although traditional cancer-fighting tools like chemotherapy and radiation remain important treatment options for doctors and patients, scientists are uncovering new approaches to attack cancer cells directly and more effectively. With recent clinical success in immunotherapy reshaping the field of oncology, the prospects for more durable and even curative responses to many cancers are on the horizon. 

The key to cancer treatment is not just to understand how cancer cells behave on their own, but to learn how they evade the body’s immune system and existing treatments. Pfizer’s pipeline of potential cancer medicines includes differentiated therapies with multiple mechanisms of action that target both the tumor itself and the immune system. We are investigating medicines for breast cancer, non-small cell lung cancer, gastric cancer, ovarian cancer, renal cell carcinoma, and hematologic malignancies, including leukemias and lymphomas. 

Click here to find out more about our global Oncology portfolio